Accelerate Your Preclinical Research By Innovative Methods.

Customizing in-vitro and in-vivo services for your success.

Recently At InnoSer

PDX/O oncology platform developments at InnoSer

Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...

Press Release: InnoSer continues to deliver critical in-vivo and in-vitro services

Press release | Leiden, 19 March 2020 InnoSer continues to deliver critical in-vivo and in-vitro services COVID-19 restrictions call for attention to prevent fully halting life sciences operations InnoSer remains committed to continuing its in-vivo and in-vitro...

Taking Precautions Against Coronavirus

Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...
THERAPEUTIC AREAS

We Specialize In

Kidney Disease (PKD)

Learn More

Parkinson’s Disease

Learn More

Oncology

Learn More

Alzheimer’s Disease

Learn More

OUR INNOVATIVE METHODS

Combining In-Vivo And In-Vitro

By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.

Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.

This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.

By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.

GET IN TOUCH WITH US

Tell Us About Your Work

We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.

OUR CLIENTS ABOUT US

Academic And Commercial Expertise

“We truly enjoyed working with the InnoSer team. They bring an outstanding scientific knowledge into the oncology field in combination with high flexibility. InnoSer provided us with and executed a preclinical study project tailored to our needs, and within the agreed timelines. We will definitely work with InnoSer for our future drug development needs.”

 

Ad van de Gorp PhD, CEO Cythura Therapeutics

“Starting a biotech company was something completely new for me. InnoSer supported me in developing the study protocol and with all additional hassle like ethical protocols, logistics, ordering study materials etc. We worked closely with the InnoSer staff and I truly appreciate their professionalism and dedication.”

 

 Joost van Bree, CEO Saillant Therapeutics

Phone

+32 (0)11 14 07 68

Headquarters

InnoSer België NV

Agoralaan A bis
3590 Diepenbeek
Belgium

 

Email

info@innoserlaboratories.com

Subsidiary

InnoSer Nederland BV

Zernikedreef 9
2333 CK Leiden
The Netherlands